伽马缺口：一种即时检测手段，可与多发性骨髓瘤的疾病负担和治疗反应相关联。
Gamma Gap: A Point-of-Care Test That Correlates With Disease Burden and Treatment Response in Multiple Myeloma.
机构信息
Hematology/Oncology Fellowship Program, MD Anderson Cancer Center, The University of Texas, Houston, TX.
Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC.
出版信息
JCO Oncol Pract. 2020 Aug;16(8):e751-e757. doi: 10.1200/JOP.19.00517. Epub 2020 Apr 2.
Abstract
PURPOSE
We performed a retrospective chart review on 393 patients with multiple myeloma (MM) to determine the utility of the gamma gap (GG).
METHODS
We calculated the difference between a patient's total serum protein and albumin as a point-of-care test for assessing disease status in MM.
RESULTS
GG is highly correlated with the level of M-spike, and the change in GG correlates with myeloma treatment response. In addition, fitted linear models were established that allow for the calculation of M-protein level from the GG within hours from blood draw.
CONCLUSION
Our study has important implications in the care of MM, particularly in countries/areas with limited resources.
摘要
目的
我们对 393 例多发性骨髓瘤（MM）患者进行了回顾性图表审查，以确定伽马间隙（GG）的实用性。
方法
我们计算了患者的总血清蛋白和白蛋白之间的差异，作为一种即时检测方法来评估 MM 中的疾病状态。
结果
GG 与 M 峰水平高度相关，GG 的变化与骨髓瘤治疗反应相关。此外，建立了拟合线性模型，允许在采血后数小时内从 GG 计算 M 蛋白水平。
结论
我们的研究对 MM 的治疗具有重要意义，特别是在资源有限的国家/地区。
相似文献
1
Gamma Gap: A Point-of-Care Test That Correlates With Disease Burden and Treatment Response in Multiple Myeloma.伽马缺口：一种即时检测手段，可与多发性骨髓瘤的疾病负担和治疗反应相关联。
JCO Oncol Pract. 2020 Aug;16(8):e751-e757. doi: 10.1200/JOP.19.00517. Epub 2020 Apr 2.
2
Machine Learning Approach for Rapid, Accurate Point-of-Care Prediction of M-Spike Values in Multiple Myeloma.机器学习方法可快速、准确地预测多发性骨髓瘤患者的 M 峰浓度值。
JCO Clin Cancer Inform. 2023 Sep;7:e2300078. doi: 10.1200/CCI.23.00078.
3
Comparison of bromcresol green and agarose protein electrophoresis for quantitation of serum albumin in multiple myeloma.溴甲酚绿法与琼脂糖蛋白电泳法在多发性骨髓瘤血清白蛋白定量中的比较
Clin Chem. 2007 Jun;53(6):1099-103. doi: 10.1373/clinchem.2007.088252. Epub 2007 Apr 26.
4
Anion gap among patients of multiple myeloma and normal individuals.多发性骨髓瘤患者与正常个体的阴离子间隙。
Clin Biochem. 2007 Feb;40(3-4):226-9. doi: 10.1016/j.clinbiochem.2006.10.011. Epub 2006 Nov 1.
5
Exploring the Clinicopathological Parameters Affecting the Outcome in Egyptian Patients with Multiple Myeloma.探索影响埃及多发性骨髓瘤患者预后的临床病理参数。
Gulf J Oncolog. 2016 Jan;1(20):51-63.
6
Is Early Palliative Care Feasible in Patients With Multiple Myeloma?多发性骨髓瘤患者实施早期姑息治疗是否可行？
J Pain Symptom Manage. 2017 Nov;54(5):692-700. doi: 10.1016/j.jpainsymman.2017.04.012. Epub 2017 Aug 12.
7
Role of urine and serum protein electrophoresis in evaluation of nephrotic-range proteinuria.尿液和血清蛋白电泳在评估肾病范围蛋白尿中的作用。
Am J Kidney Dis. 1999 Jul;34(1):135-9. doi: 10.1016/s0272-6386(99)70119-8.
8
[Multiple Myeloma - Current Status in Diagnostic Testing and Therapy].[多发性骨髓瘤——诊断检测与治疗的现状]
Z Orthop Unfall. 2017 Oct;155(5):575-586. doi: 10.1055/s-0043-110224. Epub 2017 Aug 14.
9
A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.多发性骨髓瘤中细胞因子网络综述：诊断、预后及治疗意义
Cancer. 2003 May 15;97(10):2440-52. doi: 10.1002/cncr.11072.
10
Multiple Myeloma: The Case of the Disappearing Band.多发性骨髓瘤：消失的条带病例
Lab Med. 2017 Dec 22;49(1):87-91. doi: 10.1093/labmed/lmx045.
引用本文的文献
1
Gamma gap and albumin-globulin ratio show poor sensitivity for monoclonal gammopathy screening in South Africa.在南非，γ-间隙和白蛋白-球蛋白比率对单克隆丙种球蛋白病筛查的敏感性较差。
Afr J Lab Med. 2025 Mar 26;14(1):2505. doi: 10.4102/ajlm.v14i1.2505. eCollection 2025.
2
Serum syndecan1 has the potential to reflect activity at diagnosis and predict death during follow-up in patients with ANCA-associated vasculitis.血清 syndecan1 有可能反映诊断时的活动，并预测抗中性粒细胞胞浆抗体相关性血管炎患者随访期间的死亡。
Arthritis Res Ther. 2024 Sep 20;26(1):166. doi: 10.1186/s13075-024-03393-8.
3
Gamma gap thresholds and HIV, hepatitis C, and monoclonal gammopathy.Gamma 间隙阈值与 HIV、丙型肝炎和单克隆丙种球蛋白病。
PLoS One. 2020 Jan 15;15(1):e0224977. doi: 10.1371/journal.pone.0224977. eCollection 2020.
本文引用的文献
1
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline.多发性骨髓瘤的治疗：ASCO 和 CCO 联合临床实践指南。
J Clin Oncol. 2019 May 10;37(14):1228-1263. doi: 10.1200/JCO.18.02096. Epub 2019 Apr 1.
2
Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016.多发性骨髓瘤全球负担：2016 年全球疾病负担研究的系统分析。
JAMA Oncol. 2018 Sep 1;4(9):1221-1227. doi: 10.1001/jamaoncol.2018.2128.
3
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.国际骨髓瘤工作组多发性骨髓瘤反应和微小残留病评估的共识标准。
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
4
Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.多发性骨髓瘤：2016年诊断、风险分层及管理的最新进展
Am J Hematol. 2016 Jul;91(7):719-34. doi: 10.1002/ajh.24402.
5
Monitoring IgA multiple myeloma: immunoglobulin heavy/light chain assays.监测 IgA 多发性骨髓瘤：免疫球蛋白重/轻链检测。
Clin Chem. 2015 Feb;61(2):360-7. doi: 10.1373/clinchem.2014.231985. Epub 2014 Dec 1.
6
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.多发性骨髓瘤：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2013 Oct;24 Suppl 6:vi133-7. doi: 10.1093/annonc/mdt297. Epub 2013 Aug 16.
7
Analysis of turnaround time by subdividing three phases for outpatient chemistry specimens.通过将门诊化学检验样本的三个阶段细分来分析周转时间。
Ann Clin Lab Sci. 2009 Spring;39(2):144-9.
8
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.多发性骨髓瘤的诊断、分期、风险分层及疗效评估标准。
Leukemia. 2009 Jan;23(1):3-9. doi: 10.1038/leu.2008.291. Epub 2008 Oct 30.
9
International staging system for multiple myeloma.多发性骨髓瘤国际分期系统
J Clin Oncol. 2005 May 20;23(15):3412-20. doi: 10.1200/JCO.2005.04.242. Epub 2005 Apr 4.
10
Anxiety in cancer patients.癌症患者的焦虑情绪。
Br J Cancer. 2000 Nov;83(10):1261-7. doi: 10.1054/bjoc.2000.1405.
Zotero 插件